Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- NIRVANAIndependent statistical analysis of Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04818216).
- NIRVANAIndependent statistical analysis of Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nitrate Supplementation and Exercise Tolerance in Patients With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Nitrate Supplementation and Exercise Tolerance in Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete’s Foot: Complete Statistical AnalysisIndependent statistical analysis of Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02871011).
- Nitrite Infusion in Islet Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Nitrite Infusion in Islet Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03544242).
- Nitroglycerin Infusion During Cardiac Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nitroglycerin Infusion During Cardiac Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01901419).
- Nitrous Oxide for External Cephalic Version: Complete Statistical AnalysisIndependent statistical analysis of Nitrous Oxide for External Cephalic Version: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03502915).
- Nitrous Oxide for Identifying the Intersegmental Plane in Segmentectomy: A Randomized Controlled Trial: Complete Statistical AnalysisIndependent statistical analysis of Nitrous Oxide for Identifying the Intersegmental Plane in Segmentectomy: A Randomized Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nitrous Oxide Induction Induces Amnesia in Pediatric Patients: Complete Statistical AnalysisIndependent statistical analysis of Nitrous Oxide Induction Induces Amnesia in Pediatric Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02050152).
- Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers: primary endpoint results, effect estimate…
- Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016): Complete Statistical AnalysisIndependent statistical analysis of Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016): primary endpoint results, effect estimate with confidence interval,…
- Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03693846).
- Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03055013).
- Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NK-VS-MMIndependent statistical analysis of Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): Complete Statistical AnalysisIndependent statistical analysis of NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): primary endpoint results, effect estimate with…
- NKTR-214Independent statistical analysis of A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval,…
- NMDA Antagonists in Bipolar Depression: Complete Statistical AnalysisIndependent statistical analysis of NMDA Antagonists in Bipolar Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01833897).
- NMDA Receptors in Motor Learning in Humans: Complete Statistical AnalysisIndependent statistical analysis of NMDA Receptors in Motor Learning in Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02082912).
- NMES Efficacy on Patients With NBPP: Complete Statistical AnalysisIndependent statistical analysis of NMES Efficacy on Patients With NBPP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01999465).
- NMES for Achilles Tendon Rupture: Complete Statistical AnalysisIndependent statistical analysis of NMES for Achilles Tendon Rupture: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04727047).
- No Drop Post-Op Cataract Surgery: Complete Statistical AnalysisIndependent statistical analysis of No Drop Post-Op Cataract Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03864133).
- No ShowIndependent statistical analysis of Using Behavioral Economics to Enhance Appointment Reminders and Reduce Missed Visits: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NO-ASPIRATEIndependent statistical analysis of Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02284178).
- NO-COVID-19Independent statistical analysis of Inhaled Nitric Oxide for Preventing Progression in COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04388683).
- no-cryIndependent statistical analysis of Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- No-POPPYIndependent statistical analysis of Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- NO-UTIIndependent statistical analysis of Short-course Methenamine Hippurate for Prevention of Post-operative UTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02358993).
- NOAHIndependent statistical analysis of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease: Complete Statistical AnalysisIndependent statistical analysis of Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02114216).
- NOCTIndependent statistical analysis of Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults: primary endpoint…
- NOCTETIndependent statistical analysis of Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00377962).
- NOCTURNEIndependent statistical analysis of 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…